The Price Reset: Four Ways the Next Year Breaks
July 2026
The most concentrated wave of pharmaceutical pricing reform in a generation is no longer a forecast. For boards, the question is not whether it arrives — it is how it breaks. We see four ways.
By Jeanette Fielding, Founder & Chief Executive, Confident Strategy Group
For most of the last decade, the story told about the cost of medicines was simple and mostly wrong. Headlines tracked the sticker price; it rose, and everyone concluded that medicines were simply becoming more expensive. What is happening now is different in kind. Across the United States, Europe, the United Kingdom, China, and the emerging markets, governments are rewriting how drugs are priced — at the same time and with unusual force. The sticker and the receipt have pulled apart: list prices still creep up by around four percent a year, while the net price actually collected has fallen in the US for eight years running. And a wall of deliberate government intervention is now pushing that receipt down.
The facts are no longer in doubt. In the United States, Medicare has negotiated prices on twenty-five medicines, and this spring the Supreme Court closed off the industry’s last legal escape route.[1] A one-hundred-percent tariff on patented imports has been proclaimed — softened by generous escape hatches for companies that build in America and lower their prices.[2] The negotiated price for semaglutide, the medicine behind Ozempic and Wegovy, is about 71% below its list price.[3] In India, a generic version already sells for around $15 per month.[4] None of this is speculation. It is scheduled, and much of it is now law.
So the interesting question is no longer “what is the policy?” It is “how does the next twelve months actually play out.” When we model this for clients, we don’t hand a board a single forecast dressed up as certainty — that is the least useful thing an adviser can do. We build scenarios: internally consistent accounts of how the world could break, with the forces named and the consequences drawn. Three forces do most of the work — how hard Washington chooses to enforce, how far a price cut in one country cascades into the next, and whether the supply chains and tariff carve-outs the whole system leans on hold or give way. For the year to July 2027, four futures stand out.
The first I would call Managed Transition. Washington keeps trading tariff relief for pricing deals and factory pledges; Europe holds its prices; supply stays steady — and the reset proceeds, real but on a timetable a board can plan against.
The second is Enforcement Bites. Washington collects rather than negotiates; tariffs and mandatory pricing models land with force; and pressure on inputs — roughly eighty percent of the active ingredients in American medicines come from China and India — begins to strain supply. A squeeze centered on the United States that, for the first time, reaches the low-margin generic base.
The third is Global Cascade. Even as Washington eases through deals, prices erode on their own. Cheap generics spread from market to market, and because every low price abroad now feeds the American benchmark, the quiet subsidy that had the US effectively paying more so that everyone else could pay less collapses — not by decree, but by arbitrage.
The fourth is Stacked Squeeze. The stress test — enforcement, cascade and supply strain arrive together. No one forecasts this world. Every board should nonetheless be able to survive it.
Take just one of these — Global Cascade — and follow it somewhere concrete, because it inverts a piece of conventional wisdom that has guided launches for years. The traditional playbook launches in the United States first, and deliberately high, because the US prices freely and sets the anchor from which every other market is then negotiated down. From there, a company sequences carefully — higher-priced markets before lower-priced ones — managing which prices become visible so a low number does not slip into the international reference baskets most health systems use, while HTA authorities price the medicine against the incremental value it adds over the current standard of care, unless it is genuinely first-in-class. That entire architecture rested on one assumption: that the US price sat safely at the top. In a cascade world, it no longer does. Most-Favored-Nation pricing tethers the US to the lowest price a wealthy country pays, so the largest market is now importing the very prices that the old sequencing was meant to keep out. A low or transparent price agreed anywhere stops being a contained local decision and becomes a precedent that travels all the way back up to the top. A company that still runs sequencing as a spreadsheet exercise for the commercial team may find it has repriced its flagship worldwide by accident.
“When governments, patients and payers all suspect the numbers, the company that can be trusted about its own is the one that wins the argument.”
Which points to the deeper shift, and the reason this is a communications and public-affairs challenge as much as a commercial one. In every one of these futures, the gap between the list price and the real price becomes harder to defend in public. The organizations that come through well will not be the ones that litigate hardest or hide the difference longest. They will be the ones that can explain their pricing — clearly, honestly, in plain language — before someone else explains it for them. That, not the courtroom, is the defensible position.
That is one implication, drawn from one scenario. The other three each carry their own — for the large and mid-sized branded companies weighing where to build and what to charge, and very differently for the generic and biosimilar makers who supply 9 in 10 prescriptions on margins that a single tariff could erase. There are early signals that tell you which way the world is tilting, and there are moves worth making now, whichever way it breaks. That is the work we do with boards: not predicting the future but making a business robust across plausible futures.
The reset is here. The only real choice a leader has is whether to shape it or be shaped by it. At Confident Strategy Group, we help boards do the former — through Confident ForeFront™, our intelligence, Confident Futures™, our scenario-planning process, and plain-spoken advocacy that turns a defensible position into a public one. If the next twelve months matter to your business, let’s talk before they arrive, not after.
Drawn from CSG’s Strategic Intelligence Dossier, “The Price Reset” (July 2026), which draws in turn on CMS, the White House, the US Supreme Court, IQVIA and RAND, among others. Scenario names and interpretation are CSG’s using its Confident FuturesTM process.
References
[1]Medicare has negotiated prices across two completed rounds (25 medicines); in May 2026 the US Supreme Court declined to hear the industry’s challenges, leaving the programme intact. Sources: CMS; CSG, “The Price Reset” (July 2026).
[2]Section 232 proclamation of 2 April 2026; first tranche scheduled 31 July 2026, with wide exemptions for companies that onshore manufacturing and accept lower US prices. Sources: The White House; CSG dossier.
[3]Medicare’s negotiated price for the semaglutide family, effective 2027 — about a 71% reduction on list. Sources: CMS / NPR; CSG dossier.
[4]Generic semaglutide launched in India in March 2026 at prices as low as roughly US$15 a month. Sources: Business Standard / CNBC; CSG dossier.
Our Work >